A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Phase 1/2
270
about 6 years
18+
4 sites in AL, FL, NJ +1
What this study is about
This trial is testing a treatment called MK-3120 for people with advanced solid tumors. The goal is to see if this treatment is safe and well-tolerated by participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive MK-3120
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE)
Secondary: AUC of MK-3120 Free Payload, AUC of MK-3120 Total Antibody (TAb), Area Under the Concentration-Time Curve (AUC) of MK-3120 Antibody-Drug Conjugate (ADC), Cmax of MK-3120 Free Payload, Cmax of MK-3120 TAb, Duration Of Response (DOR) Per RECIST 1.1 as Assessed by the Investigator, Maximum Concentration (Cmax) of MK-3120 ADC, Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as Assessed by the Investigator
Oncology